Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)
Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...
1 Syys 22min
Ep 86: Teaser Tudriqev (RP1) FDA Approval
James asks the big question
25 Elo 10s
Ep 87: INTerpath-001 Press Release - August 2026
In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...
25 Elo 12min
Ep 86: Tudriqev (RP1) FDA Approval
In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...
25 Elo 52min
Ep 85: Surgical considerations for TIL
In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...
28 Heinä 29min
Ep 84: Merlin CP-GEP and Castle i31-SLNB tests
In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...
24 Heinä 35min
Ep 83: Guest Megan Othus and Time of Day Administration
James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...
24 Kesä 40min
Ep 82: Best of ASCO: 2026
In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...
13 Kesä 1h 4min
